Association between Ambient Air Pollution and Outpatient Visits for Acute Bronchitis in a Chinese City

Objective To investigate the short-term association between outdoor air pollution and outpatient visits for acute bronchitis,which is a rare subject of research in the mainland of China.Methods A time-series analysis was conducted to examine the association of outdoor air pollutants with hospital outpatient visits in Shanghai by using two-year daily data（2010-2011）.Results Outdoor air pollution was found to be associated with an increased risk of outpatient visits for acute bronchitis in Shanghai.The effect estimates of air pollutants varied with the lag structures of the concentrations of the pollutants.For lag06,a 10 μg/m3 increase in the concentrations of PM10,SO2,and NO2 corresponded to 0.94%（95% CI：0.83%,1.05%）,11.12%（95% CI：10.76%,11.48%）,and 4.84%（95% CI：4.49%,5.18%） increases in hospital visits for acute bronchitis,respectively.These associations appeared to be stronger in females（P〈0.05）.Between-age differences were significant for SO2（P〈0.05）,and between-season differences were also significant for SO2（P〈0.05）.Conclusion Our analyses have provided the first evidence that the current air pollution level in China has an effect on acute bronchitis and that the rationale for further limiting air pollution levels in Shanghai should be strengthened.

Ambient Temperature and Outpatient Visits for Acute Exacerbation of Chronic Bronchitis in Shanghai: A Time Series Analysis

The association between ambient temperature and acute exacerbation of chronic bronchitis （AECB） was still unknown. Therefore, we performed an epidemiological study in a large hospital of Shanghai to explore the relationship about temperature and outpatient visit for AECB. We adopted a quasi-Poisson generalized additive models and distributed lag nonlinear models to estimate the accumulative effects of temperature on AECB across multiple days. We found significant non-linear effects of cold temperature on hospital visits for AECB, and the potential effect of cold temperature might last more than 2 weeks. The relative risks of extreme cold （first percentiles of temperature throughout the study period） and cold （10th percentile of temperature） temperature over lags 0-14 d were 2.98 [95% confidence intervals （CI）： 1.77, 5.04] and 1.63 （95% Ch 1.21, 2.19）, compared with the 25th percentile of temperature. However, we found no positive association between hospital visits and hot weather. This study showed that exposure to both extreme cold and cold temperatures were associated with increased outpatient visits for AECB in a large hospital of Shanghai.

Study on the underlying mechanism of almond and platycodon in treating acute bronchitis based on network pharmacology

Objective:Network pharmacology method was adopted in this study to screen the target of almond and platycodon of the treatment to Acute Bronchitis and exploring its mechanism of treatment.Methods:Chemical components and selected targets related to almond and platycodon were searched through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP).Through GeneCards database,OMIM database,disease targets of Acute Bronchitis were searched.Venn diagram analysis was used to screen the common targets between drugs and disease,and then the interaction network diagram of the targets was constructed by String.Cytoscape3.7.0 was applied to construct the drugcomposition-target-disease interacted network.GO Enrichment and KEGG Enrichment Analysis of Targets were based on DAVID.Results:There are 25 active components such as luteolin,acacetin and Glabridin in the almond and platycodon,corresponding to 127 targets.81 targets are obtained by mapping with 1593 targets of acute bronchitis,including PTGS2,PTGS1,AKT1,TP53,etc.KEGG enrichment analysis mainly involves Apoptosis,PI3K-Akt signaling pathway,TNF signaling pathway,T cell receptor signaling pathway,etc.Conclusion:Based on the network pharmacology,the potential mechanism of almond and platycodon in the treatment of acute bronchitis was discussed,which provides ideas and directions for further experimental research.

Systematic review of Shufeng Jiedu capsules for acute attack of chronic bronchitis

Objective:To systematically evaluate the efficacy and safety of Shufeng Jiedu Capsules in the treatment of acute attacks of chronic bronchitis.Methods:CNKI,VIP,CBM,WanFang,PubMed,EMbase,Cochrane Library and ChiCTR were searched by computer,and randomized controlled trials of Shufeng Jiedu capsules in the treatment of AECB were integrated.The retrieval time was from the date of establishing the database to December 31,2020.Meta-analysis of outcome indicators[including effective rate,C-reactive protein(CRP),lung function[FEV1%and/or FEV1/FVC],interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)]were carried out by RevMan 5.3 software,and the effective rate was tested by sequential analysis(TSA),and the quality of evidence was evaluated according to GRADE standards.Results:A total of 680 cases in 8 articles were included.Shufeng Jiedu Capsules improved the effective rate of clinicaltreatment[RR=1.20,95%CI(1.13,1.28)],improved lung function[FEV1:MD=0.33,95%CI(0.22,0.45),FEV1/FVC:MD=10.17,95%CI(8.15,12.19)],reduced CRP[MD=-7.32,95%CI(-8.42,-6.22)],IL-8[MD=-63.39,95%CI(-73.49,-53.29)],TNF-α[MD=-7.44,95%CI(-8.35,-6.53)]levels.The above differences were statistically significant(P<0.05),and no serious adverse reactions were reported in all studies.The results of TSA analysis showed that the experimental group had definite evidence for improving the efficiency.According to the GRADE evaluation system,the efficiency,TNF-αwere medium-quality evidences,FEV1 was low-quality evidence,and FEV1/FVC,CRP,and IL-8 were extremely low-quality evidence.Conclusions:The curative effect of Shufeng Jiedu capsule combined with western medicine in the treatment of AECB was better than that of single western medicine.Nevertheless,considering the limited sample size and the quality of included articles,higher quality RCTs are still needed to further confirm its effectiveness and safety.

Treatment of Cough and Dyspnea due to Acute Bronchitis by Plaster for Cough and Dyspnea——A Report of 735 Cases

In the light of the theory of treating the internal disease externally, an externally used plaster for treating cough and dyspnea due to acute bronchitis (Ke Chuan Yi Tie Kang [symbol: see text]-[symbol: see text]) was successfully applied to 735 cases of acute bronchitis (the treatment group), with the other 423 cases treated with routine western drugs as controls. The results showed that the cure rate in the treatment group was significantly higher than that in the control group (P

TCM aerosol inhalation treatment in acute exacerbations of chronic bronchitis： a meta-analysis

Objectives： To determine whether traditional Chinese medicine （TCM） aerosol inhalation treatment is effective inthe treatment of acute exacerbation of chronic bronchitis. Methods： Search double-blind randomised clinical trials（RCT） about the use of TCM aerosol inhalation in patient with acute exacerbation of chronic bronchitis via database including Chinese biomedicine literature database, Wanfang Data, CNKI, Pubmed, EMBASE and CochraneLibrary from the beginning to October 2016. Quality evaluation, data extraction and data analysis of these RCT wascarried out with reference to the Cochrane systematic review. Results： 16 studies with 738 patients in TCM aerosolinhalation group and 675 in control group were included. The results of meta-analysis showed, （1） TCM aerosolinhalation group could improve the total cure rate. （2） TCM aerosol inhalation could increase the expression of IL-2while decrease the expression of IL-8 and MDA in sputum and blood. （3） TCM aerosol inhalation could improvethe symptoms of cough, cough with sputum, cough with dyspnea and lung wet rales. It also improve the symptomsof cough, expectorate and lung wet rales. （4） Shorten the time of cough and lung rale. （5） The adverse reactionswere light only with 1 occurrence of nausea and vomiting. Conclusions： The use of TCM aerosol inhalation in thetreatment of acute exacerbation of chronic bronchitis was effective. However, the inclusion researches quality werenot very high, which only provided limited evidence for clinical application. Higher-quality randomized controlledtrials were needed for further study.

CLINICAL OBSERVATION ON TREATMENT OF ACUTE BRONCHITIS PRIMARILY WITH PRICKING-CUPPING ON BACK-SHU POINTS

To observe the clinical effect of treatment of acute bronchitis primarily with prickingcupping method on Back-shu points. Methods. The patients of acute bronchitis were randomly divided into 2 groups. In the observation group, there were 36 cases, who were treated with the integrated traditional Chinese and western medicine, primarily the pricking-cupping method on Back-shu points; while in the control group, there were 29 cases who were given the conventinal treatment of western medicine. All the 2 groups were treated for 7 days as one treating course. Results： The total effective rate of the observation group was 97.2% while that of the control group was 82,8%, so there is a significant difference between them. On the first and third days the clinical manifestations were more satisfactorily improved in the treatment group than in the control group （P 〈 0.01） and on the fifth and seventh days, the comparison showed no significant difference （P〉0.05）. Conclusion： The treatment of acute bronchitis by means of the integrated traditional Chinese and western medicine primarily with pricking-cupping method on Back-shu points is of marked therapeutic effect, simple manipulation, and little untoward effects, thus claiming the unique advantage.

Effects of montelukast sodium combined with pidotimod on acute phase protein and immune function in children with acute bronchitis

Objective: To observe the effects of montelukast sodium combined with pidotimod on acute phase protein (APP) and indexes of immunologic function in pediatric acute bronchitis treatment. Methods: A total of 180 cases children with acute bronchitis acted as research objects were randomly divided into control group (n=65) and observation group (n=63). On the basis of conventional therapy, control group was treated by plus pidotimod. On this base, observation group was treated with montelukast sodium. The changes of acute phase proteins (CRP, HP, a1-AAG and CER) and immune function (CD3+, CD4+, CD8+ and CD4+/CD8+) levels before and after treatment were observed after 2 months. Results: Before treatment, CRP, HP, a1-AAG, CER, CD3+, CD4+, CD8+ and CD4+/CD8+ levels of two groups had no statistically significant difference;CRP, HP, a1-AAG, CER, and CD8+ levels of control and observation groups decreased significantly after treatment, the decreases of observation group were more obvious than that of control group, and the levels after treatment were significantly lower than that of control groups. The levels of CD3+, CD4+ and CD4+/CD8+ in two groups after treatment were significantly higher than those before treatment. For observation group, the levels of CD3+, CD4+ and CD4+/CD8+ increased more significantly after treatment, which were significantly higher than that of the control group. Conclusion: Using Montelukast sodium combined with pidotimod can effectively reduce the children's acute phase protein levels, improve immune function, which has clinical value for the treatment of children with acute bronchitis.

宣肺止嗽合剂治疗急性支气管炎(风邪犯肺证)随机双盲多中心研究

目的观察宣肺止嗽合剂对急性支气管炎(风邪犯肺证)患者中医证候及生活质量的影响。方法采用随机、双盲、安慰剂对照研究,在19个平行中心进行观察,将240例急性支气管炎(风邪犯肺证)患者分为试验组和对照组,每组120例。试验组口服宣肺止嗽合剂,对照组口服宣肺止嗽合剂模拟剂,疗程均为7 d。比较两组中医证候(日间咳嗽、夜间咳嗽、咳痰、咽痒)积分和莱塞斯特咳嗽生命质量问卷(the Leicester cough questionnaire,LCQ)评分。结果最终完成试验者232例,其中试验组118例,对照组114例。治疗后,两组中医证候积分降低,LCQ中生理性得分、心理性得分、社会性得分和总分均升高,试验组改变更为明显(P<0.01)。两组上述指标在治疗后、治疗后较基线的差值均有统计学意义(P<0.01)。全分析集(full analysis set,FAS)及符合方案集(per protocol set,PPS)结果一致。结论宣肺止嗽合剂可以明显改善急性支气管炎(风邪犯肺证)患者中医证候,提高其生活质量。

痰热清注射液对慢性支气管炎急性发作患者肺功能及血清CRP、IL-6的影响

目的探讨痰热清注射液对慢性支气管炎急性发作患者肺功能及血清炎性因子的影响。方法98例慢性支气管炎急性发作患者随机分为两组。在对症治疗基础上,观察组给予痰热清注射液治疗,对照组给予安慰剂(5%葡萄糖注射液)干预。比较两组的肺功能、血清炎性因子水平、临床疗效、安全性。结果治疗后,观察组的FEV_(1)、FVC、FEV_(1)/FVC和TV均高于对照组,血清CRP和IL-6水平均低于对照组(P<0.05)。观察组的总有效率为95.92%,高于对照组的81.63%(P<0.05)。结论痰热清注射液可明显改善慢性支气管炎急性发作患者的肺功能,减轻炎性反应,提高临床疗效。

急性支气管炎患者C反应蛋白清除率及其与气道高反应性的相关分析

目的:探究急性支气管炎患者C反应蛋白清除率(C-reactive protein clearance rate,CRPc)与气道高反应性(airway hyperresponsiveness,AHR)的相关性,以期为临床诊断急性支气管炎患者AHR程度提供参考依据。方法:选取2020年6月~2023年6月泸州市中医医院收治的急性支气管炎患者182例作为研究对象,根据AHR程度不同将患者分为A组:轻度(n=67)、B组:中度(n=59)、C组:重度(n=56)。采用1∶1倾向性匹配的方法调整患者资料的均衡性。所有患者均进行肺部检查,采集患者清晨空腹血,应用ELISA法检测患者血清指标,C反应蛋白(C-reactive protein,CRP)水平分别于患者入院24 h内及治疗后3、5、7 d检测,通过计算获得相应的CRPc。多因素Logistic回归分析CRPc与AHR程度的相关性,分析影响AHR程度的临床因素,构建相应预测模型并进行评价。结果:3组治疗前各项指标无统计学差异。治疗后3组患者1 s用力呼气容积(forced expiratory volume in the first second,FEV 1)/用力肺活量(forced vital capacity,FVC)、每分钟最大通气量(maximum voluntary ventilation,MVV)、γ-干扰素(interferon-γ,IFN-γ)、白细胞介素-10(interleukin-10,IL-10)和FEV 1下降20%激发剂累计含量(provocation dosage when FEV 1 is reduced by 20%,PD 20 FEV 1)水平升高,CRP、人软骨糖蛋白39(human cartilage glycoprotein 39,YKL-39)和白三烯E4(leukotriene E4,LTE4)水平降低,改善效果显著,且A组患者一秒率(FEV 1/FVC)、MVV、IFN-γ、IL-10、PD 20 FEV 1水平高于其他2组,CRP、YKL-39、LTE4水平低于其他2组,改善效果较好。3组患者的CRPc-7分别为(70.66±14.85)%、(60.55±15.52)%和(48.24±14.47)%,A组患者CRPc显著高于其他2组。多因素Logistic回归分析结果显示CRPc-3(OR=0.85,95%CI:0.69~0.87)、CRPc-5(OR=0.92,95%CI:0.77~0.95)、CRPc-7(OR=0.96,95%CI:0.89~0.98)与患者AHR程度存在相关性。YKL-39和LTE4是患重症AHR的危险因素(OR>1),CRPc-3、CRPc-5、CRPc-7、IFN-γ和PD 20 FEV 1是患重症AHR的保护因素(OR<1),7个因素对预测患者为重症AHR均具有较高的价值,但是联合检测的预测价值最高。联合以上7个因素构建的模型:Logit(P)=-2.036-0.449(CRPc-3)-0.507(CRPc-5)-0.114(CRPc-7)-0.464(IFN-γ)+0.449(LTE4)+0.622(YKL-39)-0.200(PD 20 FEV 1)。当P=0.90时,约登指数最高,预测效果最好,预测准确度为83.10%,灵敏度为93.71%,特异度为78.52%。结论:轻度AHR患者CRPc高于中度及重度AHR患者。患者CRPc-3、CRPc-5、CRPc-7与AHR程度存在相关性。

家属参与共治原则对急性支气管炎患儿临床症状改善的影响

目的研究家属参与共治原则对急性支气管炎患儿临床症状改善和护理满意度的影响。方法选取2022年在我院进行治疗的急性支气管炎患儿80例为研究对象,以随机数字表法分为观察组(常规护理联合家属参与共治原则干预)及对照组(常规护理),每组40例,比较2组患儿的临床症状改善情况、肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))及呼气流量峰值(PEF)]、治疗依从性、护理满意度及生活质量[儿童生存质量测定量表(PedsQL4.0)]。结果干预后,观察组患儿喘憋、发热、肺部湿啰音及咳嗽症状消失时间以及住院时间均较对照组短(P<0.05)。干预后,2组患儿FVC、FEV_(1)、PEF均升高,且观察组较对照组高(P<0.05)。干预后,2组患儿总依从率均升高,且观察组较对照组高(P<0.05)。干预后,观察组患儿家属护理满意度较对照组高(P<0.05)。干预后,2组患儿PedsQL4.0评分均升高,且观察组较对照组高(P<0.05)。结论采用家属参与共治原则可促进急性支气管炎患儿临床症状的改善,同时改善其肺功能,提高其治疗依从性、护理满意度及生活质量。

二陈止嗽润肺方结合穴位敷贴治疗老年急性支气管炎效果观察

目的评估二陈止嗽润肺方结合穴位敷贴治疗老年急性支气管炎临床效果。方法研究纳入94例老年急性支气管炎患者(2019年1月—2021年12月)进行研究,将纳入患者以随机数字表法分为常规治疗组与中医治疗组,各47例,常规治疗组患者采取西医常规治疗,中医治疗组患者在常规西医治疗基础上结合二陈止嗽润肺方及穴位敷贴治疗,各组数据观察:疗效、治疗前后中医证候(咳嗽气粗、口干口苦、痰多黄稠、烦躁不安等)积分变化、动脉血氧分压(PaO_(2))及动脉血二氧化碳分压(PaCO_(2))水平变化、用力肺活量(FVC)、第1秒用力呼气容积(FEV1)及最大呼气峰流速百分比(PEF%)指标变化、血清白细胞介素-4(IL-4)及白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平变化、不良反应。结果中医治疗组患者治疗总有效率(95.74%,45/47)高于常规治疗组(82.98%,39/47),P<0.05;治疗前,各组患者中医证候(咳嗽气粗、口干口苦、痰多黄稠、烦躁不安等)积分、PaO_(2)及PaCO_(2)、FVC、FEV1、PEF%、IL-4、IL-6、hs-CRP等指标均改善,中医治疗组患者中医证候(咳嗽气粗、口干口苦、痰多黄稠、烦躁不安等)积分、PaO_(2)及PaCO_(2)、FVC、FEV1、PEF%、IL-4、IL-6、hs-CRP等指标治疗后均优于常规治疗组,P<0.05;常规治疗组患者1例恶心,中医治疗组患者1例皮肤过敏,两组不良反应率均较低,P>0.05。结论二陈止嗽润肺方结合穴位敷贴治疗老年急性支气管炎临床效果显著,患者症状及肺功能改善,不良反应少,治疗安全可靠。

慢性支气管炎急性期患者的常规药物结合自拟宣肺化痰汤治疗作用

目的分析急性期慢性支气管炎患者的常规药物结合自拟宣肺化痰汤治疗作用。方法回顾性选取江苏省句容市中医院于2021年6月—2023年2月收治的76例慢性支气管炎急性期患者的临床资料,依照用药方案不同分为对照组(常规药物)、观察组(常规药物结合自拟宣肺化痰汤),各38例。比较两组临床疗效、肺功能、血气指标、炎性因子水平、不良反应发生率。结果观察组治疗总有效率为97.37%(37/38),高于对照组的76.32%(29/38),差异有统计学意义(χ^(2)=7.369,P<0.05)。用药前,两组肺功能、血气指标以及炎性因子水平比较,差异无统计学意义(P均>0.05)。用药后,观察组用力肺活量、第1秒用力呼气量、氧分压、二氧化碳分压、白细胞介素-10、超敏C反应蛋白均优于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论慢性支气管炎急性期患者,采用常规药物+自拟宣肺化痰汤治疗的效果更好,可改善肺功能及血气指标,减轻炎症反应,且安全性高。

宣肺合剂联合西药治疗慢性支气管炎急性发作的疗效

目的 观察宣肺合剂联合西药治疗慢性支气管炎急性发作的疗效,及其对血清CXC趋化因子受体4(CXCR4)、半乳糖凝集素-9(Gal-9)和趋化因子3(CCL3)水平的影响。方法 选择2020年1月-2021年12月在本院诊治的慢性支气管炎急性发作的患者96例,分为观察组和对照组各48例。对照组予以常规西药治疗,观察组在对照组的基础上予以宣肺合剂治疗。比较两组治疗后的疗效和不良反应,比较治疗前后喘息、咳痰、咳嗽积分、第一秒用力呼气量(FEV1)、用力肺活量(FVC)、最大通气量(MVV)、CXCR4、Gal-9和CCL3水平的变化。结果 观察组的总有效率为95.83%,对照组的总有效率为79.17%,观察组显著优于对照组(P<0.05);两组的不良反应率差异无统计学意义(P>0.05)。两组治疗前喘息、咳痰、咳嗽积分、FEV1、FVC、MVV、CXCR4、Gal-9和CCL3水平差异无统计学意义(P>0.05);治疗后两组的喘息、咳痰、咳嗽积分、CXCR4、Gal-9和CCL3水平均较治疗前显著降低,与对照组比较观察组出现明显降低(均P<0.01);治疗后两组的FEV1、FVC和MVV水平均较治疗前显著升高,与对照组比较观察组显著升高(均P<0.01)。结论 宣肺合剂能够提高西药对慢性支气管炎急性发作的疗效,缓解症状和改善肺功能,其机制可能与降低机体CXCR4、Gal-9和CCL3的水平有关。

布地奈德联合氨溴索对儿童急性支气管炎症状改善及机体炎症反应的影响

目的探究布地奈德联合氨溴索对儿童急性支气管炎症状改善及机体炎症反应的影响。方法随机选取2023年6—11月滕州市妇幼保健院收治的100例儿童急性支气管炎患儿为研究对象,根据不同用药方案分为常规组和研究组,每组50例。常规组采用氨溴索治疗,研究组采用氨溴索与布地奈德联合治疗。对比两组患儿的治疗总有效率、临床症状改善时间、治疗前后炎症介质水平。结果研究组治疗总有效率为98.00%(49/50),高于常规组的80.00%(40/50),差异有统计学意义(χ^(2)=8.274,P=0.004)。研究组喘鸣音改善时间、咳嗽改善时间、气促改善时间及湿啰音消失时间均短于常规组,差异有统计学意义(P均<0.05)。治疗前,两组患儿的炎症介质水平对比,差异无统计学意义(P>0.05);治疗后,研究组炎症介质水平低于常规组,差异有统计学意义(P<0.05)。结论对儿童急性支气管炎患儿使用布地奈德联合氨溴索治疗,能减轻机体炎症反应,缩短症状改善时间。

清金化痰汤加减对痰热郁肺型慢性支气管炎急性发作期的临床治疗效果

目的 探究清金化痰汤加减对痰热郁肺型慢性支气管炎急性发作期患者的应用价值。方法选取2019年1月—2022年10月青岛市黄岛区人民医院收治的80例痰热郁肺型慢性支气管炎急性发作期患者进行研究。依据抽签法分为对照组(40例)与研究组(40例),分别实施常规治疗、常规治疗+清金化痰汤治疗。比较两组炎症因子、治疗效果与中医证候积分等。结果 研究组治疗有效率为97.50%,高于对照组的72.50%,差异有统计学意义(χ^(2)=9.804,P<0.05)。研究组复发率低于对照组,差异有统计学意义(P<0.05)。研究组中医证候积分低于对照组,差异有统计学意义(P<0.05)。研究组炎症因子相关指标较对照组低,差异有统计学意义(P<0.05)。结论 清金化痰汤加减应用于痰热郁肺型慢性支气管炎急性发作期患者时,对炎症因子水平及中医证候的改善有一定促进作用,可提高整体治疗效果。

羧甲司坦口服溶液联合重组人干扰素α1b治疗小儿急性喘息性支气管炎的效果

目的分析急性喘息性支气管炎患儿接受重组人干扰素α1b单药与联合羧甲司坦口服溶液治疗的效果。方法回顾性分析2021年6月至2023年6月医院收治的100例急性喘息性支气管炎患儿资料,按不同治疗方案分为对照组、观察组,各50例。对照组接受重组人干扰素α1b治疗,观察组接受羧甲司坦口服溶液联合重组人干扰素α1b治疗。比较两组临床疗效、主要症状缓解时间、气道炎症相关因子[趋化因子配体3(CCL3)、高迁移率族蛋白B1(HMGB1)、α1-酸性糖蛋白(α1-AG)]、T淋巴细胞(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))及不良反应。结果观察组临床总有效率高于对照组(P<0.05)。治疗后观察组气促、喘息、咳嗽、肺部音等症状缓解时间降低(P<0.05)。治疗4、7 d后,两组CCL3、HMGB1、α1-AG较治疗前下降,且观察组低于对照组(P<0.05);两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)较治疗前升高,且观察组高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论羧甲司坦口服溶液联合重组人干扰素α1b治疗急性喘息性支气管炎,可抑制气道炎症,调节机体免疫,促进症状缓解,疗效确切,且安全性高。

预警护理对急性支气管炎患儿病情改善情况的影响研究

目的 分析预警护理对急性支气管炎患儿病情改善情况的影响。方法 选取2021年1月至2022年12月期间漯河医学高等专科学校第二附属医院收治的86例急性支气管炎患儿,在区间随机法辅助下开展组别划分,对照组(43例),接受常规护理;实验组(43例),在常规护理基础上实施预警护理。比较两组患儿症状消失时间、护理前后肺功能指标[用力肺活量(FVC)、呼气流量峰值(PEF)、一秒用力吸气容积(FEV1)]变化情况、急性支气管炎并发症发生情况及家属对护理服务的满意度。结果 实验组发热消失时间、咳嗽消失时间、喘息消失时间、肺部湿啰音消失时间均短于对照组,差异有统计学意义(P <0.05)。护理前,两组间肺功能指标比较,差异无统计学意义(P> 0.05);护理后,两组FVC、PEF、FEV1均明显上升,且实验组高于对照组,差异有统计学意义(P <0.05)。实验组急性支气管炎并发症发生率(2.33%)低于对照组(16.28%),差异有统计学意义(P <0.05)。实验组满意度评分显著高于对照组,差异有统计学意义(P <0.05)。结论 对急性支气管炎患儿实施预警护理有利于患儿康复与病情改善,在缩短症状消失时间、预防并发症、改善肺功能等方面均有突出体现,值得应用。

金振口服液对支气管炎豚鼠气道炎症和咳嗽的影响

目的研究金振口服液(JZOL)对支气管炎咳嗽模型豚鼠气道炎症反应和气管炎咳嗽的影响。方法将40只豚鼠随机分为模型组、空白对照组、JZOL高剂量组、JZOL低剂量组和阿莫西林组5组,制备支气管炎咳嗽模型,给药后观察各组咳嗽敏感性;ELISA法检测血清IL-1β、CRP含量;qPCR技术测定气管组织CysLTs、MCP-1、TRPA1、CGRP mRNA水平;HE染色法观察肺组织病理变化。结果与模型组比较,JZOL可以降低咳嗽敏感性;血清IL-1β、CRP含量虽未见显著差异,但JZOL具有明显下调趋势,其中JZOL高剂量组最低,作用强度较阿莫西林组明显;JZOL可抑制气管组织中MCP-1、CGRP、CysLTs和TRPA1的mRNA表达;JZOL对肺组织病理变化有改善作用,病变程度由高至低依次为JZOL低剂量组、阿莫西林组、JZOL高剂量组。结论JZOL可以抑制气道炎症,缓解支气管炎咳嗽,其可能通过调控TRPA1通路发挥止咳作用。